Sebastian
Real TAKHZYRO patient
REIMAGINE the way you treat HAE
TAKHZYRO (lanadelumab-flyo) is clinically proven to reduce attacks with the possibility of zero attacks for periods of time -- the only every-2-weeks hereditary angioedema (HAE) treatment evaluated in a 2.5 year study.1-5
Deirdre
Wife and caregiver
Sebastian
Real TAKHZYRO patient
Rediscover Prevention
The safety and efficacy of TAKHZYRO (lanadelumab-flyo) were assessed in a 26-week pivotal trial of 125 HAE patients ≥12 years of age. The primary efficacy endpoint was the rate of investigator-confirmed attacks during the treatment period compared to placebo.1,6
Significant reduction in mean attack rate* vs placebo at 6.5 months (26 weeks)1,6
In the Pivotal Trial
REDUCTION
IN ATTACKS
Vs Placebo
(Adjusted P<0.001)1†
- TAKHZYRO (lanadelumab-flyo) every 4 weeks resulted in a 73% reduction in attacks vs placebo (Adjusted P<0.001)1†
- Mean monthly attack rate at baseline (during run-in period): 3.52 for TAKHZYRO every 2 weeks (n=27); 3.71 for TAKHZYRO every 4 weeks (n=29); 4.02 for placebo (n=41)6
- Mean monthly attack rate (during treatment): 0.26 for TAKHZYRO every 2 weeks; 0.53 for TAKHZYRO every 4 weeks; 1.97 for placebo1
All data presented are for TAKHZYRO 300 mg every 2 weeks unless otherwise indicated.
The pivotal trial was a multicenter, double-blind, parallel-group, placebo controlled, dose-ranging study which assessed the safety and efficacy of TAKHZYRO in 125 patients with HAE type I or II (≥12 years of age). Patients were randomized to receive TAKHZYRO 150 mg every 4 weeks (n=28), TAKHZYRO 300 mg every 4 weeks (n=29), TAKHZYRO 300 mg every 2 weeks (n=27), or placebo (n=41) for 26 weeks (6.5 months, where 1 month was defined as 28 days). Prior to randomization, patients ≥18 years of age were required to complete a ≥2-week long-term prophylaxis washout period. All patients then entered a 4-week run-in period to determine the baseline HAE attack rate. All patients with ≥1 investigator-confirmed HAE attack during the run-in period were eligible for study enrollment and randomization. The primary efficacy endpoint was the rate of investigator-confirmed attacks during the treatment period (time frame: from Day 0 to Day 182) (Adjusted P<0.001 vs placebo for all; adjusted P values for multiple testing).1,6
*Mean monthly attack rate: number of attacks/4 weeks.
†Adjusted P values for multiple testing.
Rethink dosing and administration
Just 1 subcutaneous self-injection every 2 weeks, requiring no reconstitution.1
The recommended starting dose is 300 mg every 2 weeks. TAKHZYRO every 4 weeks is also effective and may be considered if the patient is well-controlled (eg, attack free) for more than 6 months.1
Refine the approach
The first and only monoclonal antibody (mAb) for HAE, TAKHZYRO inhibits plasma kallikrein activity, a critical regulator of bradykinin production, to help prevent HAE attacks. TAKHZYRO is non-plasma derived.1,3-5
Camila
Real TAKHZYRO patient
TAKHZYRO
Quick Start Program
Get patients started on TAKHZYRO
Get patients started on TAKHZYRO
Takeda will provide eligible patients with immediate access to TAKHZYRO at no cost during potential delays in commercial insurance coverage determinations.‡ Once enrolled, patients will receive assistance from OnePath®, a product support program.
‡Timing is dependent upon when the forms are received by OnePath®. The Quick Start Program is available to all commercially insured patients ≥12 years of age who are US residents with a confirmed diagnosis of HAE. Takeda and its affiliates reserve the right to change or discontinue this program at any time, without notice. Void where prohibited by law. This program does not constitute a financial assistance program.
